I-Mab to Present Givastomig Phase 1 Dose Data at SITC 2024

I-Mab, a United States-based global biotechnology firm dedicated to developing advanced immunotherapies for cancer treatment, has announced a significant presentation at the upcoming Society for Immunotherapy of Cancer (SITC) conference. The conference is scheduled for November 6-10, 2024, in Houston, Texas. At this event, I-Mab will present a poster detailing Phase 1 data on the optimized dosage of givastomig (TJ033721/ABL111), a pioneering bispecific antibody targeting Claudin18.2 and 4-1BB.

The poster, titled "Optimal dose estimation using an integrated approach from Phase I data of givastomig, a novel Claudin18.2×4-1BB bispecific antibody," will be presented by J.A. Yanez. It will be exhibited in the Poster Hall at the George R. Brown Convention Center on Saturday, November 9, 2024, from 9:00 am to 8:30 pm CDT.

Givastomig is an innovative bispecific antibody designed to target Claudin (CLDN) 18.2-positive tumor cells and activate T cells through the 4-1BB pathway specifically within the tumor microenvironment. This targeting enhances its binding and anti-tumor activity while reducing liver toxicity and systemic immunotoxicity compared to other 4-1BB-based therapies. The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to givastomig in March 2022 for the treatment of gastric cancer, including cancers at the gastroesophageal junction.

Currently, a Phase 1b study is underway to evaluate the combination of givastomig with standard-of-care treatments, including nivolumab and chemotherapy, in patients newly diagnosed with gastric and gastroesophageal cancers. This study is registered under the identifier NCT04900818.

The givastomig program is a collaborative effort between I-Mab and ABL Bio. Under this global partnership, I-Mab leads the development and holds equal worldwide rights, excluding China and South Korea, with ABL Bio.

I-Mab is a biotechnology company with a focus on creating highly differentiated immunotherapies to treat cancer. The company operates out of Rockville, Maryland, and Short Hills, New Jersey.